FDX-6058
Fulcrum’s Sickle Cell Disease Program Resumes as FDA Lifts 6-Month Hold
Anika Sharma
Fulcrum Therapeutics’ ambitions in the realm of sickle cell disease (SCD) have been revitalised after a six-month hiatus. The FDA ...
most recent
Latest News, Deals, Pharma
Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer
Pharma, Clinical Trials, Latest News
Vertex Halts Phase 2 Lung Therapy, Reevaluates DMD Drug’s Clinical Path
Latest News, Clinical Trials, Pharma
Ventyx Halts TYK2 Inhibitor Despite Phase 2 Success, Stock Plummets 70%
Latest News, Pharma
J&J MedTech Plans US Clinical Trials for Ottava Surgical Robot in Late 2024
